Alnylam Pharmaceuticals Inc
F:DUL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Alnylam Pharmaceuticals Inc
F:DUL
|
US |
|
Hiab Oyj
F:C1C1
|
FI |
|
E
|
EVI Industries Inc
AMEX:EVI
|
US |
|
G
|
Giglio.Com SpA
MIL:GCOM
|
IT |
|
N
|
Novartis AG
SWB:NOTA
|
CH |
|
Newell Brands Inc
NASDAQ:NWL
|
US |
|
Nissan Chemical Corp
OTC:NNCHF
|
JP |
|
NGK Spark Plug Co Ltd
OTC:NGKSY
|
JP |
|
Triboo SpA
MIL:TB
|
IT |
|
Andersons Inc
NASDAQ:ANDE
|
US |
|
Atoss Software AG
F:AOF
|
DE |
|
W
|
Woodside Energy Group Ltd
F:WOP0
|
AU |
|
Swiss Prime Site AG
SIX:SPSN
|
CH |
|
E
|
Endeavour Silver Corp
F:EJD
|
CA |
|
V
|
Vertex Pharmaceuticals Inc
XMUN:VX1
|
US |
|
N
|
Netflix Inc
SWB:NFC
|
US |
|
S
|
Swiss Prime Site AG
DUS:SU1N
|
CH |
|
Novartis AG
OTC:NVSEF
|
CH |
|
E
|
Exotic Food PCL
SET:XO
|
TH |
|
Avi Ltd
F:IZ60
|
ZA |
|
C
|
CBRE Group Inc
SWB:RF6
|
US |
Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals develops medicines based on RNA interference, or RNAi, a way to silence disease-causing genes. It does not make broad consumer products; it focuses on prescription drugs for serious genetic and rare diseases, along with some more common conditions where turning off a specific gene can help. Its main work is discovering, testing, and selling these therapies to physicians and patients through normal pharmaceutical channels. The company makes money by selling approved drugs and, in some cases, from collaboration deals tied to research, development, or product commercialization. Its customers are doctors, hospitals, specialty pharmacies, and health systems that prescribe its medicines, with insurers and government payers also playing a major role because these drugs are usually expensive specialty treatments. Alnylam’s role in the industry is to turn a new genetic science into targeted medicines that can address diseases where older drugs often treat symptoms rather than the root cause. What makes Alnylam different is its focus on RNAi as a drug platform. Instead of building a wide catalog of unrelated products, it concentrates on one core technology that can be applied to different diseases by silencing specific genes. That gives the company a clear niche in biopharma: it is both a drug developer and one of the main commercial proof points for RNAi medicines.
Alnylam Pharmaceuticals develops medicines based on RNA interference, or RNAi, a way to silence disease-causing genes. It does not make broad consumer products; it focuses on prescription drugs for serious genetic and rare diseases, along with some more common conditions where turning off a specific gene can help. Its main work is discovering, testing, and selling these therapies to physicians and patients through normal pharmaceutical channels.
The company makes money by selling approved drugs and, in some cases, from collaboration deals tied to research, development, or product commercialization. Its customers are doctors, hospitals, specialty pharmacies, and health systems that prescribe its medicines, with insurers and government payers also playing a major role because these drugs are usually expensive specialty treatments. Alnylam’s role in the industry is to turn a new genetic science into targeted medicines that can address diseases where older drugs often treat symptoms rather than the root cause.
What makes Alnylam different is its focus on RNAi as a drug platform. Instead of building a wide catalog of unrelated products, it concentrates on one core technology that can be applied to different diseases by silencing specific genes. That gives the company a clear niche in biopharma: it is both a drug developer and one of the main commercial proof points for RNAi medicines.
Revenue: Alnylam reported total global net product revenue of approximately $1.2 billion, up 74% year over year, with TTR revenue topping $1 billion for the first time in a quarter.
Guidance cut: The company lowered 2026 total net product revenue guidance to $4.7 billion to $5.1 billion, mainly because early second-line demand in the U.S. was boosted by pent-up demand that has now normalized.
AMVUTTRA strength: AMVUTTRA generated more than $1 billion in quarterly revenue and continues to gain traction in first-line ATTR cardiomyopathy, which management says is now about 80% of new starts.
Competition: Management said the failed CARDIO-TTRansform study does not change its confidence in TRITON-CM and may improve AMVUTTRA’s competitive position, especially with tafamidis U.S. generic entry now expected in mid-2031.
Pipeline: Alnylam highlighted progress across a broad pipeline, including new Phase II starts for ALN-6400 and mivelsiran and several data readouts expected in the second half of 2026.
Cash: The company ended the quarter with $3.3 billion in cash, cash equivalents and marketable securities, up from $2.9 billion at year-end 2025.